Plus   Neg

Stock Alert: Myovant Sciences Shares Fall

Shares of clinical-stage biopharmaceutical company Myovant Sciences Ltd. (MYOV) are losing more than 3 percent in the morning trade on Monday, at $12.31. The stock has been trading in a range of $4.14 to $26.02 in the past 52 weeks.

The company's lead investigational drug candidate is Relugolix, a small molecule, GnRH receptor antagonist.

In November, Myovant Sciences reported results from HERO, the company's phase III study of once-daily, oral Relugolix in men with advanced prostate cancer. In the study, 96.7 percent of men receiving once-daily, oral Relugolix achieved sustained testosterone suppression to castrate levels.

Relugolix is also under a phase III clinical program consisting of two international, replicate pivotal clinical studies, dubbed SPIRIT 1 and SPIRIT 2, in women with endometriosis-associated pain.

Myovant expects to report top-line results from the SPIRIT 2 and SPIRIT 1 studies in the first and second quarters of the calendar year 2020, respectively.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT